Corrigendum—Full Exemption of Certain COVID-19 Point-of-care Tests Under the COVID-19 Public Health Response (Point-of-care Tests) Order 2021

Pursuant to clause 9 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, Dr Ashley Bloomfield, Director-General of Health, exempt the following point-of-care rapid antigen tests from all prohibitions under clause 7 of the Order.

Product name(s): StrongStep SARS-CoV-2 Antigen Rapid Test

Manufacturer (country): Nanjing Liming Bio-Products Co., Ltd (China)

Sample type(s): Nasal swab

Product configuration: Professional or self-test of any package size

Product name(s): CLUNGENE COVID-19 Antigen Rapid Test

Manufacturer (country): Hangzhou Clongene Biotech Co., Ltd (China)

Sample type(s): Nasal swab

Product configuration: Self-test of any package size

Product name(s): INDICAID COVID-19 Rapid Antigen Test

Manufacturer (country): PHASE Scientific International, Ltd. (Hong Kong and United States of America)

Sample type(s): Nasal swab

Product configuration: Professional or self-test of any package size

Dated at Wellington this 28th day of April 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health, Ministry of Health.

Note: This notice replaces the notice published in the New Zealand Gazette, 29 April 2022, Notice No. 2022-go1608.

Corrigendum—Full Exemption of Certain COVID-19 Point-of-care Tests Under the COVID-19 Public Health Response (Point-of-care Tests) Order 2021

Tags

Notice Number